POZYTYWNA OPINIA CHMP OTWIERA DROGĘ DO SZERSZEGO STOSOWANIA LEKU REPATHA® FIRMY AMGEN PRZED WYSTĄPIENIEM PIERWSZEGO ZAWAŁU SERCA LUB UDARU MÓZGU

RegulatoryapprovedRepathaPositive

AI Analysis

Summary

Amgen's Repatha received a positive CHMP opinion for use in primary prevention of myocardial infarction and stroke, supported by Phase 3 clinical trial data demonstrating significant risk reduction. This represents the first PCSK9 inhibitor with proven efficacy in this prevention indication.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Positive CHMP opinion for prevention of first myocardial infarction and stroke

Importance:7/10

Sentiment:

0.85

CHMP opinioncardiovascularPCSK9 inhibitorregulatory approvalprimary prevention

Related Companies

$AMGN

Read the original article

Published by PR Newswire Biotech on July 30, 2026 12:15 PM

Read Original